Pathstone Family Office’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pathstone Family Office’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$298K	Buy	+832	New	+$321K	﹤0.01%	1311
2023 Q2	–	Sell	-483	Closed	-$275K	–	1248
2023 Q1	$275K	Sell	483 -894	-65%	-$418K	﹤0.01%	953
2022 Q4	$573K	Buy	1,377 +118	+9%	+$47.6K	﹤0.01%	1040
2022 Q3	$525K	Buy	+1,259	New	+$628K	﹤0.01%	1060
2021 Q1	–	Sell	-24	Closed	-$14K	–	735
2020 Q4	$14K	Buy	+24	New	+$13.7K	﹤0.01%	797

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Family Office's BIO Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2023: 832 shares worth $298K. The stake represents ﹤0.01% of the portfolio and ranks #1311 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in BIO as recently as Q1 2023.

Pathstone Family Office first reported a position in BIO in Q4 2020 and has held it in 5 quarters since. The position peaked at $573K in Q4 2022. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

Pathstone Family Office held 832 shares of Bio-Rad Laboratories Class A worth $298K as of Q3 2023.
Bio-Rad Laboratories Class A was a new Pathstone Family Office position in Q3 2023.
Bio-Rad Laboratories Class A made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1311 holding.
Pathstone Family Office first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and has held it in 5 quarters since.
Pathstone Family Office's Bio-Rad Laboratories Class A position peaked at $573K in Q4 2022.
467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.